Abstract:We read with great interest the article by Mineo and colleagues 1 exploring the role of Fc␥IIB, an inhibitory receptor of Fc␥IIs, on C-reactive protein (CRP)-mediated endothelial dysfunction.Mineo et al examined the mechanisms of CRP actions on endothelium by testing the hypothesis that CRP attenuates endothelial NO synthase (eNOS) activation in vitro.The investigators found that CRPinduced declines in NO production promote monocyte adhesion to endothelium.They further investigated the role of Fc␥ receptors, which display high affinity for CRP and modulate CRP actions.They found that, in Fc␥RIIB ϩ/ϩ mice, CRP blunts acetylcholine-induced increases in carotid artery vascular conductance, and that, in contrast, CRP enhances acetylcholine responses in Fc␥RIIB Ϫ/Ϫ mice.They concluded that Fc␥RIIB mediates CRP inhibition of eNOS.At first glance, their results appear to be contradictory to previous reports by our own group 2,3 and by Gill et al. 4 In our study, not only Fc␥RIIB-mediated inhibitory effect on experimental autoimmune myocarditis in rats 2 but Fc␥RIIB-mediated antiatherosclerotic effect in apolipoprotein E-deficient mice 3 were demonstrated, using immunoglobulin preparations.Gill et al 4 demonstrated the targeting effect of immunoglobulin on adhesion molecules using ischemiareperfusion model in cats, suggesting the downregulation of adhesion molecules via Fc receptors.3][4] The precise effect of Fc␥RIIB on cardiovascular inflammatory cascades may depend on experimental models.Such opposite activatory and inhibitory actions of Fc␥RIIB against inflammation may occur, depending on the dose used and the experimental conditions.In fact, there are Fc␥RIIA, an activatory receptor, and Fc␥RIIB, an inhibitory receptor, in humans, but only Fc␥RIIB has been identified in mice. 5ineo et al 1 also explored the fact that Fc␥RIIB is expressed in human endothelial cells and in mouse endothelium.It is well known that CRP levels are strongly correlated with increased risk for cardiovascular inflammatory diseases. 6,7Taken together, they proposed a CRP-modulating novel therapy by Fc␥RIIB for preventing cardiovascular complications in multiple inflammatory and autoimmune disorders.We agree with their proposal, because of the great pathogenetic contribution of Fc␥IIs in cardiovascular inflammatory diseases.

Effect of Immunoregulation of IVIG to the Expression of Inhibitory Fc Receptor

Fc Gamma Riiia Negatively Impacts Humoral Immune Responses But Not Overall Lung Inflammation In An Ovalbumin-Induced Allergic Asthma Mouse Model

FcγRIIb expression on B cells is associated with treatment efficacy for acute rejection after kidney transplantation

[Regulation of Fc Receptor Expression by Immune Complexes on Neutrophils and U937 Cells].

Fc Gamma Riii-Dependent Inhibition Of Interferon-Gamma Responses Mediates Suppressive Effects Of Intravenous Immune Globulin

Intravenous immunoglobulin induces IL-4 in human basophils by signaling through surface-bound IgE

Observation on Immuno-Function and Clinical Treatment of 106 Cases of CFC of Children by IVIg

ROLE OF ACCESSORY CELLS IN THE IVIG-MEDIATED INHIBITION OF T CELL ACTIVATION (48.5)

Fc-gamma receptor expression and cytokine responses to intravenous human immunoglobulin in whole blood from non-pregnant and pregnant women and newborns

Low Expression of FCGRIIB in Macrophages of Immune Thrombocytopenia-Affected Individuals

Dose-related regulatory effect of intravenous immunoglobulin on dendritic cells-mediated immune response.

Suppressive effects of intravenous immunoglobulin (IVIG) on human umbilical cord blood immune cells.

Antigen-induced oligomerization of the B cell receptor is an early target of Fc gamma RIIB inhibition.

Effect of Fibrinogen and Its Degradation Products on the Expression of Intercellular Adhesion Molecule-1 in Coculture System of Human Umbilical Vein Endothelial Cells

Effect of Intravenous Immunoglobulin on Cell Immunity of Myasthenia Gravis Patients

Dissecting the Molecular Mechanism of IVIg Therapy: the Interaction Between Serum IgG and DC-SIGN is Independent of Antibody Glycoform or Fc Domain.

Through an ITIM-independent mechanism the FcγRIIB blocks B cell activation by disrupting the colocalized microclustering of the B cell receptor and CD19.

FcγIIB and Cardiovascular Inflammatory Disease

Effect of Chimeric Intron on the Expression of Anti-bFGF Antibody Genes in 293T Cells

Clinical Efficacy and Immunoregulation Effects of Iguratimod on Th Subsets in Patients with Rheumatoid Arthritis

Transmembrane domain dependent inhibitory function of FcγRIIB